Psychedelics Incannex secures financing deal valued at US$60 million It will fund clinical trials that are currently underway and general corporate expenses Rowan DunneSeptember 10, 2024
Psychedelics PharmAla Biotech first to get Special Access Program authorization for its MDMA Health Canada granted PharmAla approval to provide its LaNeo product to a physician that will facilitate MDMA-assisted therapy Rowan DunneMay 16, 2023
Business Incannex appoints Eurofins to manufacture chewable nicotine and opioid treatment drug The CannQuit-N and CannQuit-O products utilize CBD to reduce anxiety and cravings Rowan DunneNovember 25, 2022
Cannabis Incannex receives positive feedback from FDA for its brain injury treatment drug The company says the FDA is very interested in developing IHL-216A for the treatment of TBI Rowan DunneOctober 11, 2022
Cannabis Incannex partners with Curia to accelerate production of IHL-216A New inhalable drug containing CBD designed for efficacious treatment of brain injuries Rowan DunneAugust 2, 2022